IS IT POSSIBLE TO DIAGNOSE LOW RISK MYELODYSPLASTIC SYNDROME (MDS) BY FLOW CYTOMETRY?

被引：0
|
作者：
Atilla, E. [1 ]
Atilla, P. Ataca [1 ]
Turedi, O. [2 ]
Bozdag, S. Civriz [1 ]
Toprak, S. Kocak [1 ]
Akan, H. [1 ]
Beksac, M. [1 ]
Arslan, O. [1 ]
Topcuoglu, P. [1 ]
Ozcan, M. [1 ]
Ilhan, O. [1 ]
Ruhi, H. I. [2 ]
Gurman, G. [1 ]
Dalva, K. [1 ]
机构：
[1] Ankara Univ, Sch Med, Dept Hematol, Ankara, Turkey
[2] Ankara Univ, Sch Med, Dept Genet, Ankara, Turkey
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1227
引用
收藏
页码：506 / 506
页数：1
相关论文
共 50 条
  • [41] MYELODYSPLASTIC SYNDROME: VALIDATION OF FLOW CYTOMETRY MULTILINEAGE SCORE SYSTEM
    Araujo, Helena
    Correia, Rodolfo
    Bento, Laiz
    Ioshida, Marcia
    Barroso, Rodrigo
    Bacal, Nydia
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2018, 40 : 10 - 10
  • [42] Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome
    M G Della Porta
    L Malcovati
    R Invernizzi
    E Travaglino
    C Pascutto
    M Maffioli
    A Gallì
    S Boggi
    D Pietra
    L Vanelli
    C Marseglia
    S Levi
    P Arosio
    M Lazzarino
    M Cazzola
    Leukemia, 2006, 20 : 549 - 555
  • [43] Diagnostic flow cytometry for low-grade myelodysplastic syndromes
    Ogata, Kiyoyuki
    HEMATOLOGICAL ONCOLOGY, 2008, 26 (04) : 193 - 198
  • [44] Utility of peripheral blood flow cytometry in differentiating low grade versus high grade myelodysplastic syndromes (MDS) and in the evaluation of cytopenias
    Rashidi, Hooman H.
    Xu, Xiangdong
    Wang, Huan-You
    Shafi, Nelofar Q.
    Rameshkumar, Karuna
    Messer, Karen
    Smith, Brian R.
    Rose, Michal G.
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2012, 5 (03): : 224 - 230
  • [45] MULTICENTER COMPARISON OF CD34+MYELOID CELL COUNT BY FLOW CYTOMETRY IN LOW-RISK MYELODYSPLASTIC SYNDROME. IS IT FEASIBLE?
    Font, P.
    Subira, D.
    Matarraz, S.
    Benavente, C.
    Cedena, T.
    Morado, M.
    Perez-Corral, A.
    Bellon, J. M.
    Diez-Martin, J. L.
    LEUKEMIA RESEARCH, 2017, 55 : S98 - S99
  • [46] Alemtuzumab treatment for aplastic anemia (AA) and low-risk myelodysplastic syndrome (MDS): Preliminary results
    Lee, Je-Hwan
    Choi, Seong-Jun
    Lee, Jung-Hee
    Seol, Miee
    Lee, Young-Shin
    Sim, Soo-Yung
    Ryu, Seong-Gil
    Kang, Young-Ah
    Lee, Kyoo-Hyung
    BLOOD, 2007, 110 (11) : 438A - 438A
  • [47] Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine
    Greenberg, Peter L.
    Garcia-Manero, Guillermo
    Moore, Michael R.
    Damon, Lloyd E.
    Roboz, Gail J.
    Wei, Helen
    Kantarjian, Hagop
    Franklin, Janet L.
    BLOOD, 2009, 114 (22) : 703 - 703
  • [48] Multicenter comparison of CD34+myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible?
    Font, Patricia
    Subira, Dolores
    Matarraz, Sergio
    Benavente, Celina
    Teresa Cedena, Maria
    Morado, Marta
    Perez Corral, Ana
    Maria Bellon, Jose
    Luis Diez-Martin, Jose
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2018, 94 (03) : 527 - 535
  • [49] Distribution of clonal cells in flow cytometry-defined subpopulations of patients with myelodysplastic syndromes (MDS)
    Roehnert, M.
    Oelschlaegel, U.
    Sockel, K.
    Parmentier, S.
    Wermke, M.
    Von Bonin, M.
    Klotsche, C.
    Thiede, C.
    Ehninger, G.
    Bornhaeuser, M.
    Mohr, B.
    Platzbecker, U.
    LEUKEMIA RESEARCH, 2013, 37 : S48 - S49
  • [50] Delayed response to lenalidomide in International Prognostic Scoring System (IPSS) low risk myelodysplastic syndrome (MDS)
    Tubb, Erev E.
    Besa, Emmanuel C.
    Giagounidis, Aristoteles
    Fonseca, Gustavo A.
    BLOOD, 2007, 110 (11) : 433A - 434A
12345